Skip Navigation

Annals of Oncology 2005 16(11):1717; doi:10.1093/annonc/mdi374
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 European Society for Medical Oncology

In this issue

In this issue

The first 10% of the full text of this article appears below.


   CNS metastases in HER2-positive breast cancer
 
Trastuzumab, a humanized monoclonal antibody that recognizes the extracellular domain of HER2, has been studied in a variety of clinical settings, including a randomized trial of chemotherapy with or without trastuzumab as first-line treatment for HER2-positive metastatic breast cancer. That study showed that the addition of trastuzumab improved response rate, and progression-free and overall survival. Recently, HER2 overexpression and trastuzumab-based therapy has been suggested to be associated with increased . . . [Full Text of this Article]


   Imatinib in patients with c-Kit-expressing relapsed SCLC
 

   Prognostic significance of bone marrow magnetic resonance imaging in previously untreated multiple myeloma
 

   Molecular staging of the sentinel lymph node in melanoma patients
 

   Quote
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?